Profusa shares surge 61.42% premarket after launching Lumee tissue oxygen monitoring for CRO market.

Profusa (Nasdaq: PFSA) surged 61.42% in premarket trading following the announcement of its commercial launch of the Lumee tissue oxygen monitoring system for the contract research organization (CRO) market. The company began immediate revenue generation through research-use-only kits and service-enabled platforms, targeting the $47.9 billion global CRO market, which is projected to grow at a 7% CAGR. The initiative enables real-time tissue oxygenation data for drug development applications, addressing demand for advanced biosensing tools in pharmaceutical R&D. Profusa also appointed Sean Givens, an experienced executive, to lead commercialization efforts, signaling strategic momentum. The move positions the company to capitalize on rising industry demand for predictive biological insights, reducing late-stage drug development risks and aligning with regulatory trends toward new approach methodologies.